Richard Vandlen

13.2k total citations · 3 hit papers
76 papers, 7.4k citations indexed

About

Richard Vandlen is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Richard Vandlen has authored 76 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 23 papers in Radiology, Nuclear Medicine and Imaging and 20 papers in Oncology. Recurrent topics in Richard Vandlen's work include Monoclonal and Polyclonal Antibodies Research (22 papers), HER2/EGFR in Cancer Research (15 papers) and Receptor Mechanisms and Signaling (9 papers). Richard Vandlen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), HER2/EGFR in Cancer Research (15 papers) and Receptor Mechanisms and Signaling (9 papers). Richard Vandlen collaborates with scholars based in United States, France and Belgium. Richard Vandlen's co-authors include Robert W. Akita, Mark X. Sliwkowski, Michael A. Raftery, Daniel G. Yansura, Helga Raab, Vincent Fitzpatrick, Richard A. Cerione, Kermit L. Carraway, Andrew Nuijens and James Lee and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Richard Vandlen

76 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Heregulin, a Specific Activator of p185 ^erbB2

1992 845 citations Mark X. Sliwkowski, Robert W. Akita et al. profile →
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

1994 560 citations Mark X. Sliwkowski, Gabriele Schaefer et al. Journal of Biological Chemistry profile →
The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency

1996 507 citations Bruce A. Keyt, Lea T. Berleau et al. Journal of Biological Chemistry profile →

Peers

Richard Vandlen

ONCOL

RNMI

IMMUN

CMN

Aviv Gazit Israel

Alonzo H. Ross United States

Abraham M. de Vos United States

Mark Ultsch United States

John Laterra United States

Angelo Corti Italy

Germaine Fuh United States

G Carpenter United States

Luis M. Montuenga Spain

Samuel R. Denmeade United States

Aviv Gazit Israel

Richard Vandlen

5.3k ×1.3

3.3k ×1.4

ONCOL

717 ×0.4

RNMI

1.3k ×1.4

IMMUN

449 ×0.5

CMN

Citations per year, relative to Richard Vandlen Richard Vandlen (= 1×) peers Aviv Gazit

Countries citing papers authored by Richard Vandlen

Since Specialization

Citations

This map shows the geographic impact of Richard Vandlen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Vandlen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Vandlen more than expected).

Fields of papers citing papers by Richard Vandlen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Vandlen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Vandlen. The network helps show where Richard Vandlen may publish in the future.

Co-authorship network of co-authors of Richard Vandlen

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Vandlen. A scholar is included among the top collaborators of Richard Vandlen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Vandlen. Richard Vandlen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Jianhua, Jean-Michel Vernes, Christopher A. Nelson, et al.. (2014). Real-time immuno-polymerase chain reaction in a 384-well format: Detection of vascular endothelial growth factor and epidermal growth factor-like domain 7. Analytical Biochemistry. 463. 61–66. 9 indexed citations

Ultsch, Mark, Jack Bevers, Gerald Nakamura, et al.. (2013). Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. Journal of Molecular Biology. 425(8). 1330–1339. 142 indexed citations

Scheer, Justin M., Wendy Sandoval, J. Michael Elliott, et al.. (2012). Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators. PLoS ONE. 7(12). e51817–e51817. 32 indexed citations

Kim, Hok Seon, James A. Ernst, Jenny Boström, et al.. (2012). Translation Levels Control Multi-Spanning Membrane Protein Expression. PLoS ONE. 7(4). e35844–e35844. 7 indexed citations

Jackman, Janet, Yongmei Chen, Arthur Huang, et al.. (2010). Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling. Journal of Biological Chemistry. 285(27). 20850–20859. 68 indexed citations

Junutula, Jagath R., Kelly M. Flagella, Richard Graham, et al.. (2010). Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Clinical Cancer Research. 16(19). 4769–4778. 214 indexed citations

Chung, Inhee, Robert W. Akita, Richard Vandlen, et al.. (2010). Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 464(7289). 783–787. 436 indexed citations

Junutula, Jagath R., Sunil Bhakta, Helga Raab, et al.. (2008). Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. Journal of Immunological Methods. 332(1-2). 41–52. 128 indexed citations

Pisabarro, M. Teresa, Mandy Kwong, Racquel Corpuz, et al.. (2006). Cutting Edge: Novel Human Dendritic Cell- and Monocyte-Attracting Chemokine-Like Protein Identified by Fold Recognition Methods. The Journal of Immunology. 176(4). 2069–2073. 82 indexed citations

10.

Fu, Ling, Linu M. John, Sean H. Adams, et al.. (2004). Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient Diabetes. Endocrinology. 145(6). 2594–2603. 481 indexed citations

11.

Fitzpatrick, Vincent, Paul I. Pisacane, Richard Vandlen, & Mark X. Sliwkowski. (1998). Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Letters. 431(1). 102–106. 56 indexed citations

12.

Chen, Longchuan, Vincent Fitzpatrick, Richard Vandlen, & Armen H. Tashjian. (1997). Both Overlapping and Distinct Signaling Pathways for Somatostatin Receptor Subtypes SSTR1 and SSTR2 in Pituitary Cells. Journal of Biological Chemistry. 272(30). 18666–18672. 35 indexed citations

13.

Nelson, Christopher S., Barbara Moffat, William J. Henzel, et al.. (1996). Glycerophosphorylethanolamine (GPEA) Identified as an Hepatocyte Growth Stimulator in Liver Extracts. Experimental Cell Research. 229(1). 20–26. 13 indexed citations

14.

Keyt, Bruce A., Lea T. Berleau, Hung Van Nguyen, et al.. (1996). The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency. Journal of Biological Chemistry. 271(13). 7788–7795. 507 indexed citations breakdown →

15.

Cossum, Paul A., et al.. (1992). The Disposition of a Human Relaxin (hRlx-2) in Pregnant and Nonpregnant Rats. Pharmaceutical Research. 9(3). 419–424. 17 indexed citations

16.

Stewart, Dennis R., et al.. (1991). Affinity Purification and Sequence Determination of Equine Relaxin*. Endocrinology. 129(1). 375–383. 19 indexed citations

17.

Stults, John T., James H. Bourell, Eleanor Canova‐Davis, et al.. (1990). Structural characterization by mass spectrometry of native and recombinant human relaxin. Journal of Mass Spectrometry. 19(11). 655–664. 60 indexed citations

18.

Quattrin, Teresa, Christine H Albini, José Cara, et al.. (1988). Quantitation of Urinary Somatomedin-C and Growth Hormone in Preterm and Fullterm Infants and Normal Children. The Journal of Clinical Endocrinology & Metabolism. 66(4). 792–797. 27 indexed citations

19.

Albini, Christine H, Teresa Quattrin, Richard Vandlen, & Margaret H. MacGillivray. (1988). Quantitation of Urinary Growth Hormone in Children with Normal and Abnormal Growth. Pediatric Research. 23(1). 89–92. 48 indexed citations

20.

Quattrin, Teresa, Christine H Albini, Richard Vandlen, & Margaret H. MacGillivray. (1987). Quantitation of Urinary Somatomedin-C in Children With Normal and Abnormal Growth. The Journal of Clinical Endocrinology & Metabolism. 65(6). 1168–1171. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact